By Mill Chart
Last update: Mar 31, 2025
Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is suited for growth investing. Investors should of course do their own research, but we spotted HALOZYME THERAPEUTICS INC showing up in our Minervini growth screen, so it may be worth spending some more time on it.
The Minervini Trend Template is a set of technical criteria designed to identify stocks in strong uptrends. We can check all the boxes for HALO:
ChartMill employs its own High Growth Momentum Rating (HGM) system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth and profitability factors, such as EPS and revenue growth, as well as accelleration, surprises and revision history. HALO has earned a 5:
ChartMill incorporates a Setup Rating in its analysis, which measures the extent of consolidation in a stock over recent days and weeks. This rating, ranging from 0 to 10, is updated daily and takes into account multiple short-term technical indicators. The current setup rating for HALO is 5:
HALO has an excellent technical rating and also presents a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period. A pullback is taking place, which may present a nice opportunity for an entry.
For an up to date full technical analysis you can check the technical report of HALO
More ideas for high growth momentum stocks can be found on ChartMill in our High Growth Momentum + Trend Template screen.
This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
52.02
+3.07 (+6.27%)
Find more stocks in the Stock Screener
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and an attractive valuation, making it a standout in the biotech sector for investors seeking affordable growth opportunities.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
HALOZYME THERAPEUTICS (NASDAQ:HALO) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a compelling pick for value investors.